We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+14.54%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.47B
AUM Growth
-$118M
Cap. Flow
-$497M
Cap. Flow %
-20.15%
Top 10 Hldgs %
35.06%
Holding
147
New
13
Increased
26
Reduced
28
Closed
38

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$70.1M
2
ADPT
Adeptus Health Inc
ADPT
+$48.6M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$22.8M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$17.2M
5
XNPT
XENOPORT, INC.
XNPT
+$15.9M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$41.3M
2
NXTM
NxStage Medical Inc.
NXTM
+$32.2M
3
ELGX
Endologix Inc
ELGX
+$28.8M
4
GSK icon
GSK
GSK
+$24.8M
5
LOXO
Loxo Oncology, Inc
LOXO
+$22.5M

Sector Composition

Rank Sector Weight
1 Healthcare 68.33%
2 Financials 4.33%
3 Technology 0.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$253M 10.26%
11,684,801
+3,603,394
+45% +$70.1M
NXTM
2
DELISTED
NxStage Medical Inc.
NXTM
$101M 4.08%
4,589,000
-1,729,050
-27% -$32.2M
DYAX
3
DELISTED
DYAX CORPORATION
DYAX
$84.3M 3.42%
2,242,073
-615,700
-22% -$19.8M
ADPT
4
DELISTED
Adeptus Health Inc
ADPT
$71.3M 2.89%
1,307,908
+762,580
+140% +$48.6M
GSK icon
5
GSK
GSK
$104B
$67.6M 2.74%
1,340,308
-485,870
-27% -$24.8M
AET
6
DELISTED
Aetna Inc
AET
$63.9M 2.59%
591,465
-44,574
-7% -$4.82M
DVA icon
7
DaVita
DVA
$15.2B
$57.3M 2.32%
822,000
+106,000
+15% +$7.77M
VTRS icon
8
Viatris
VTRS
$20.1B
$57.1M 2.31%
1,056,000
-219,000
-17% -$10.5M
VNDA icon
9
Vanda Pharmaceuticals
VNDA
$327M
$55.8M 2.26%
5,996,691
+1,212,534
+25% +$12.1M
GILD icon
10
CALL
Gilead Sciences
GILD
$167B
$53.8M 2.18%
+532,000
New +$55.4M
TEVA icon
11
Teva Pharmaceuticals
TEVA
$37.3B
$53.5M 2.17%
815,000
+200,000
+33% +$12.4M
AVDL
12
DELISTED
Avadel Pharmaceuticals
AVDL
$49.7M 2.02%
4,072,809
– –
GBT
13
DELISTED
Global Blood Therapeutics, Inc.
GBT
$37.6M 1.52%
1,163,811
+273,191
+31% +$11.8M
ARRY
14
DELISTED
Array Biopharma Inc
ARRY
$36.8M 1.49%
8,729,361
-1,000,000
-10% -$4.56M
TEVA icon
15
CALL
Teva Pharmaceuticals
TEVA
$37.3B
$36.1M 1.46%
550,000
– –
PTLA
16
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$35.2M 1.43%
683,749
+353,912
+107% +$17.2M
SAGE
17
DELISTED
Sage Therapeutics
SAGE
$34.9M 1.42%
598,854
-50,210
-8% -$2.49M
XNPT
18
DELISTED
XENOPORT, INC.
XNPT
$34.5M 1.4%
6,287,374
+2,842,000
+82% +$15.9M
AAC
19
DELISTED
AAC Holdings
AAC
$34M 1.38%
1,782,094
+180,718
+11% +$4.27M
INFI
20
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$33.8M 1.37%
4,305,288
+394,567
+10% +$3.4M
UAM
21
DELISTED
Universal American Corp
UAM
$33.5M 1.36%
4,789,027
-141,760
-3% -$1.01M
WBA
22
DELISTED
Walgreens Boots Alliance
WBA
$32.9M 1.33%
386,457
-77,000
-17% -$6.54M
EHTH icon
23
eHealth
EHTH
$47.3M
$32.6M 1.32%
3,264,588
– –
TVTY
24
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$31.7M 1.29%
2,465,042
– –
CRL icon
25
Charles River Laboratories
CRL
$10.8B
$30.3M 1.23%
377,188
-204,000
-35% -$14.7M
1
2 3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q4 2015 Portfolio in Review

As of Q4 2015, Deerfield Management held 147 positions worth $2.47B, down 4.6% from $2.59B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Deerfield Management withdrew a net $497M in Q4 2015, closing 38 positions and reducing 28 holdings. Its most notable exit was bluebird bio, an estimated $41.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 69% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Five Prime Therapeutics, Inc. worth $28.2M.

  • Deerfield Management's largest Q4 2015 buy was Five Prime Therapeutics, Inc.: 680,000 shares worth $28.2M.
  • Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015, an estimated $70.1M increase.
  • Deerfield Management's biggest Q4 2015 reduction was NxStage Medical Inc., cutting an estimated $32.2M.
  • Deerfield Management fully exited bluebird bio in Q4 2015, selling an estimated $41.3M.
  • Deerfield Management's ten largest holdings make up 35% of its $2.47B portfolio in Q4 2015.
  • Deerfield Management opened 13 new positions and closed 38 in Q4 2015.
  • Deerfield Management's portfolio value fell 4.6% quarter-over-quarter to $2.47B.

Based on Deerfield Management's 13F filing for Q4 2015, filed 16 Feb 2016.